Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.48 |
| ▸ | PDE5A | O76074 | 7/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31738660 | 0.81 | ADORA2A (0.55) | ADORA2AADORA1LMNATP53HPGD | |
| SCHEMBL6864690 | 0.81 | ADORA2A (0.55) | ADORA2AADORA1LMNATP53HPGD | |
| SCHEMBL1662517 | 0.76 | ADORA1 (0.47) | ADORA2AADORA1LMNATP53HPGD | |
| SCHEMBL2328936 | 0.74 | RECQL (0.60) | ADORA2AADORA1LMNATP53HPGD | |
| SCHEMBL29219273 | 0.74 | PDE5A (0.49) | PDE5AMAPT | |
| SCHEMBL19151780 | 0.74 | PDE5A (0.50) | PDE5AL3MBTL1CYP1A2CYP2C19 | |
| SCHEMBL174461 | 0.74 | PDE5A (0.52) | PDE5A | |
| SCHEMBL29219198 | 0.74 | PDE5A (0.49) | PDE5A | |
| SCHEMBL29011924 | 0.74 | PDE5A (0.49) | ADORA2AADORA1PDE5AALDH1A1 | |
| SCHEMBL19480643 | 0.73 | PDE5A (0.58) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257398-A1 | PYRIMIDINE-BASED TRICYCLIC COMPOUND AND USE THEREOF | CHIA TAL TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257398-A1 | PYRIMIDINE-BASED TRICYCLIC COMPOUND AND USE THEREOF | TYMP, TYMS, DPYD | ADORA2A 396/4885ADORA1 562/4885PDE5A 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.